Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma
Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma
复制标题
与 SUMO1 相比，SUMO1P3 的表达是肺腺癌患者预后的独立预测因子
DOI：
10.12659/msm.916887
复制
发表时间：
2019-09-06
影响因子：
3.1
通讯作者：
Fang, Aiping
中科院分区：
文献类型：
--
作者：
Su, Xiaolan;Wan, Yang;Fang, Aiping
背景：小泛素样修饰符 1 (SUMO1) 和小泛素样修饰符 1 假基因 3 (SUMO1P3) 是长非编码 RNA (lncRNA)。 SUMO1 和 SUMO1P3 表达在非小细胞肺癌 (NSCLC) 中的预后意义尚不清楚。本研究旨在利用癌症基因组图谱 (TCGA) 的临床、遗传和生存数据，分析 SUMO1 和 SUMO1P3 表达在 NSCLC 两种主要亚型——肺腺癌 (LUAD) 和肺鳞状细胞癌 (LUSC) 中的预后意义。 材料/方法：数据来自 TCGA 和计算机生存分析。 被执行。比较 LUAD 和 LUSC 患者之间 SUMO1 和 SUMO1P3 的表达。患者结果评估为完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）和疾病进展（PD）。无复发生存期（RFS）定义为从初次手术到肺癌局部或远处复发的生存时间。结果：SUMO1P3在LUSC和LUAD组织中较邻近正常肺组织显着升高，并与SUMO1显着共表达。在初次或后续治疗后，RFS 降低的 LUAD 患者中 SUMO1P3 表达显着增加，但 LUSC 患者中没有显着增加。尽管SUMO1或SUMO1P3高表达的LUAD患者与低表达组相比RFS降低，但单因素和多因素分析显示，只有SUMO1P3表达与RFS降低独立相关（HR，1.418；95% CI，1.041-1.930；p=0.027）。结论：SUMO1P3表达是LUAD患者RFS降低的独立指标。
Background: The small ubiquitin-like modifier 1 (SUMO1) and small ubiquitin-like modifier 1 pseudogene 3 (SUMO1P3) are long noncoding RNAs (lncRNAs). The prognostic significance of SUMO1 and SUMO1P3 expression in non-small cell lung cancer (NSCLC) remains unclear. This study aimed to use clinical, genetic, and survival data from the Cancer Genome Atlas (TCGA), to analyze the prognostic significance of SUMO1 and SUMO1P3 expression in the two main subtypes of NSCLC, lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).Material/Methods: Data were acquired from TCGA and in silico survival analysis was performed. SUMO1 and SUMO1P3 expression were compared between patients with LUAD and LUSC. Patient outcome was assessed as complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). Recurrence-free survival (RFS) was defined as the survival time from primary surgery to the time of locoregional or distant recurrence of lung cancer.Results: SUMO1P3 was significantly increased in LUSC and LUAD tissues compared with adjacent normal lung tissue and was significantly co-expressed with SUMO1. SUMO1P3 expression was significantly increased in patients with LUAD but not LUSC with reduced RFS after primary or follow-up treatment. Although patients with LUAD who had high SUMO1 or SUMO1P3 expression had reduced RFS compared with low expression groups, univariate and multivariate analysis showed that only SUMO1P3 expression was independently associated reduced RFS (HR, 1.418; 95% CI, 1.041-1.930; p=0.027).Conclusions: SUMO1P3 expression was an independent indicator of reduced RFS in patients with LUAD.